UK markets closed

Inhibitor Therapeutics, Inc. (INTI)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.12060.0000 (0.00%)
At close: 11:24AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 20.75M
Enterprise value 9.21M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.93
Enterprise value/revenue N/A
Enterprise value/EBITDA -105.24

Trading information

Stock price history

Beta (5Y monthly) -0.81
52-week change 3210.26%
S&P500 52-week change 326.27%
52-week high 30.3000
52-week low 30.0130
50-day moving average 30.0794
200-day moving average 30.0732

Share statistics

Avg vol (3-month) 310.52k
Avg vol (10-day) 311.31k
Shares outstanding 5172.02M
Implied shares outstanding 6172.02M
Float 875.56M
% held by insiders 158.49%
% held by institutions 10.00%
Shares short (15 Jan 2010) 419.88k
Short ratio (15 Jan 2010) 40.08
Short % of float (15 Jan 2010) 40.36%
Short % of shares outstanding (15 Jan 2010) 40.23%
Shares short (prior month 15 Dec 2009) 440

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-20.34%
Return on equity (ttm)-44.57%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-3.03M
Diluted EPS (ttm)-0.0200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.84M
Total cash per share (mrq)0.05
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)13.45
Book value per share (mrq)0.03

Cash flow statement

Operating cash flow (ttm)-2.7M
Levered free cash flow (ttm)-1.8M